Nemaura Medical Inc. (NMRD)
Market Cap | 22.37M |
Revenue (ttm) | 397,322 |
Net Income (ttm) | -13.08M |
Shares Out | 31.51M |
EPS (ttm) | -0.54 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 15,988 |
Open | 0.700 |
Previous Close | 0.726 |
Day's Range | 0.700 - 0.773 |
52-Week Range | 0.700 - 4.576 |
Beta | -0.02 |
Analysts | Buy |
Price Target | 8.84 (+1,145.07%) |
Earnings Date | Feb 24, 2023 |
About NMRD
Nemaura Medical Inc., a medical technology company, discovers, develops, and commercializes diagnostic medical devices. It provides sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for NMRD stock is "Buy." The 12-month stock price forecast is $8.84, which is an increase of 1,145.07% from the latest price.
News

Nemaura Medical to Participate in Fireside Chat Hosted by EF Hutton
LOUGHBOROUGH, March 21, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive...

Nemaura Includes Insulin on List of Drugs Eligible for EU DuoPack License Agreement
LOUGHBOROUGH, March 15, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive...

Nemaura Medical Announces Receipt of Notice from Nasdaq
LOUGHBOROUGH, March 09, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive w...

Nemaura Medical, Inc. (NMRD) Reports Q3 Loss, Lags Revenue Estimates
Nemaura Medical, Inc. (NMRD) delivered earnings and revenue surprises of 61.11% and 98.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stoc...

Nemaura Medical Reports Fiscal Third Quarter 2023 Results and Provides Business Update
Loughborough, England, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-i...

Nemaura Medical to Participate in Fireside Chat at the MicroCap Rodeo Winter Wonderland Best Ideas 2023 Virtual Conference
Loughborough, England, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable sensors and ...

Nemaura Medical Announces Closing of Approximately $8.4 Million Registered Direct Offering and Concurrent Private Placement
LOUGHBOROUGH, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive w...

Nemaura Medical Announces Pricing of Approximately $8.4 Million Registered Direct Offering and Concurrent Private Placement
LOUGHBOROUGH, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive w...

Nemaura Medical Receives First Purchase Order from U.S. Health Provider HealthFleet
LOUGHBOROUGH, England--(BUSINESS WIRE)--Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable...

Nemaura Medical Reports Initial Patient Data from UK NHS Miboko Study that Demonstrates Weight Loss in 100% of Participants
LOUGHBOROUGH, England--(BUSINESS WIRE)--Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable...

Nemaura Medical to Present at the Sidoti & Co. Micro Cap Virtual Conference
Loughborough, England, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic de...

Nemaura Medical to Present at the Planet MIcroCap Showcase: Virtual 2022
Loughborough, England, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic de...

Nemaura Commences Pilot Program of Miboko with the NHS in the United Kingdom
LOUGHBOROUGH, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive we...

Nemaura Medical, Inc. (NMRD) Reports Q2 Loss, Misses Revenue Estimates
Nemaura Medical, Inc. (NMRD) delivered earnings and revenue surprises of 0% and 75.33%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Nemaura Medical to Present at the Bernstein 2ND Annual CGM Disruptors Conference
Loughborough, England, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic de...

Nemaura Medical, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
ORLANDO, FL / ACCESSWIRE / November 4, 2022 / RedChip Companies will air a new interview with Nemaura Medical, Inc. (NASDAQ:NMRD) ("Nemaura" or the "Company"), a medical technology company focused on ...

Nemaura Receives Provisional Purchase Order from Middle East Licensee TPMENA
LOUGHBOROUGH, ENGLAND, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercialising nonin...

Nemaura and EVERSANA sign preliminary agreement for large-scale launch of Nemaura's Diabetes Management Program in the U.S.
CHICAGO and LOUGHBOROUGH, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc.(NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercialising non...

Nemaura Medical to Present at the 24th Annual H.C. Wainwright Global Investment Conference
Loughborough, England, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing a daily disposable, wearable gluc...

Nemaura Medical, Inc. (NMRD) Reports Q1 Loss, Lags Revenue Estimates
Nemaura Medical, Inc. (NMRD) delivered earnings and revenue surprises of -6.25% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Nemaura Medical Reports Fiscal First Quarter 2023 Results and Provides Business Update
Loughborough, England, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a dai...

Nemaura Medical Strengthens Balance Sheet with Further Non-Dilutive Funding
Loughborough, England, May 23, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on commercializing a daily disposable wearable glucose sensor and sup...

MySugarWatch Continues Large-Scale Awareness Campaign Around Nemaura Medical's sugarBEAT Non-Invasive Continuous Glucose Monitor Commencing Direct-to-Consumer Campaign in Daily Mail
Loughborough, England, May 17, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on developing and commercializing wearable diagnostic devices and sup...

Nemaura Medical to Present at the Planet MicroCap Showcase 2022
Loughborough, England, April 25, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing wearable diagnostic devices and s...

Nemaura Medical to Present at the Maxim Group 2022 Virtual Growth Conference
Loughborough, England, March 24, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing wearable diagnostic devices and s...